Shares of BioArctic AB (STO:BIOA B) climbed 4.8% following the announcement of its partner Eisai's robust sales figures for ...

Children who inherit genetic mutations from parents with early-onset Alzheimer’s typically show signs of dementia at the same ...

The FDA has approved the sBLA for once every 4 weeks lecanemab-irmb (Leqembi®) intravenous maintenance dosing.

Following the president’s recent executive order dismantling diversity, equity, and inclusion policies, the main page for the ...

In the latest development, the European Commission has asked the EMA's human medicines committee, the CHMP, to take a look at ...

A monthly 10 mg/mL maintenance dose of Leqembi had the same effects on mild Alzheimer’s symptoms as biweekly dose, research ...

Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatmentAlzheimer's disease progression does ...

The monthly maintenance regimen, which offers a more convenient frequency than the initially approved treatment schedule for ...

The reassessment of Leqembi’s safety data follows the agency’s previous recommendation of the drug for use in the EU.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

The European Commission has requested its medicines regulator to consider safety information on Eisai and Biogen's ...

Alzheimer's disease progression does not stop after plaque clearance; ongoing treatment with LEQEMBI can slow disease progression and prolong the benefits of therapy TOKYO and CAMBRIDGE ...